| RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary … PG Steg, SR Mehta, JW Jukema, GYH Lip, CM Gibson, F Kovar, P Kala, ... European heart journal 32 (20), 2541-2554, 2011 | 220 | 2011 |
| Dieta y riesgo cardiovascular en España (DRECE II). Descripción de la evolución del perfil cardiovascular JAG Fuentes, J Gómez-Jerique, AG de la Cámarac, MÁ Rubio, ... Medicina clínica 115 (19), 726-729, 2000 | 128 | 2000 |
| Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN) P Van Kerrebroeck, F Haab, JC Angulo, V Vik, F Katona, ... European urology 64 (3), 398-407, 2013 | 99 | 2013 |
| Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 … D de Zeeuw, RW Renfurm, G Bakris, P Rossing, V Perkovic, FF Hou, ... The Lancet Diabetes & Endocrinology 6 (12), 925-933, 2018 | 36 | 2018 |
| Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol KM Gooding, C Lienczewski, M Papale, N Koivuviita, M Maziarz, ... BMC nephrology 21, 1-11, 2020 | 32 | 2020 |
| % JM: a SAS macro to fit jointly generalized mixed models for longitudinal data and time-to-event responses A Garcia-Hernandez, D Rizopoulos Journal of Statistical Software 84, 1-29, 2018 | 32 | 2018 |
| Is increasing urinary albumin a better marker for microvascular than for macrovascular complication of type 2 diabetes mellitus? JL Herrera-Pombo, M Aguilar-Diosdado, F Hawkins, MM Campos, ... Nephron Clinical Practice 101 (3), c116-c121, 2005 | 27 | 2005 |
| Primary outcomes of the VIDI study: Phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema QD Nguyen, YJ Sepah, B Berger, D Brown, DV Do, A Garcia-Hernandez, ... International journal of retina and vitreous 5, 1-14, 2019 | 14 | 2019 |
| Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects T Kadokura, M Kashiwa, D Groenendaal, M Heeringa, R Mol, ... Biopharmaceutics & drug disposition 34 (8), 431-441, 2013 | 14 | 2013 |
| Pharmacokinetic evaluation of the interactions of amenamevir (ASP2151) with ketoconazole, rifampicin, midazolam, and warfarin in healthy adults T Kusawake, M den Adel, D Groenendaal-van de Meent, ... Advances in therapy 34, 2466-2480, 2017 | 11 | 2017 |
| Combined Use of an Alpha-Adrenergic Receptor Antagonist and an Anti-Muscarinic Agent KJ Van Charldorp, BJF Bosman, MMA Klaver, AG Hernandez, ... US Patent App. 13/127,178, 2012 | 11 | 2012 |
| The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P‐glycoprotein and CYP3A4 D Groenendaal, G Strabach, A Garcia‐Hernandez, T Kadokura, ... British Journal of Clinical Pharmacology 75 (2), 440-449, 2013 | 10 | 2013 |
| MMRM vs joint modeling of longitudinal responses and time to study drug discontinuation in clinical trials using a “de jure” estimand A García‐Hernandez, T Pérez, MC Pardo, D Rizopoulos Pharmaceutical Statistics 19 (6), 909-927, 2020 | 9 | 2020 |
| Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage LUTS: results from a phase 2, dose-finding study (SATURN) P Van Kerrebroeck, F Haab, JC Angulo, V Vik, F Katona, ... Eur Urol 64 (3), 398-407, 2013 | 9 | 2013 |
| Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin T Kadokura, D Groenendaal, M Heeringa, R Mol, F Verheggen, ... European journal of drug metabolism and pharmacokinetics 39, 1-9, 2014 | 8 | 2014 |
| The pharmacokinetics of YM150, an oral direct factor Xa inhibitor are not affected to a clinically relevant degree by strong inhibition or induction of CYP3A4 and P-GP M Heeringa, D Groenendaal, G Strabach, A Garcia-Hernandez, ... JOURNAL OF THROMBOSIS AND HAEMOSTASIS 9, 359-360, 2011 | 8 | 2011 |
| A note on the validity and reliability of multi-criteria decision analysis for the benefit–risk assessment of medicines A Garcia-Hernandez Drug safety 38 (11), 1049-1057, 2015 | 7 | 2015 |
| Quality-of-life–adjusted hazard of death: A formulation of the quality-adjusted life-years model of use in benefit-risk assessment A Garcia-Hernandez Value in health 17 (2), 275-279, 2014 | 5 | 2014 |
| Co-administration of darexaban (YM150), an oral direct factor Xa inhibitor, with acetylsalicylic acid, clopidogrel and naproxen: no evidence of clinically relevant interactions M Heeringa, D Groenendaal, G Strabach, A Garcia-Hernandez, ... J Thromb Hemost 9 (Suppl 2), 360, 2007 | 5 | 2007 |
| Descripción de la mortalidad quirúrgica de la corrección de cardiopatías congénitas: experiencia institucional 2000-2005 VR Castillo, GA Jaramillo, AE Durán, A Montero, A Hernández, ... Rev Col Cardiol 12, 268, 2006 | 5 | 2006 |
